Acute coronary syndromes: advances in antithrombotics.

Nilusha Gukathasan, Roxana Mehran

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Contemporary management of acute coronary syndromes (ACS) has evolved to include rapid revascularization, potent antithrombotic, and antiplatelets, all of which reduce the risk of ischemic complications. Despite these advances, recurrent ischemic and bleeding event rates are still substantial. This increased risk post-percutaneous coronary intervention (PCI) has been the seminal event leading to recent clinical trials evaluating more potent antiplatelet drugs (prasugrel, ticagrelor, and protease-activated receptor-1 [PAR-1] inhibitors) and novel oral anticoagulants (NOAC). Ideally, an effective anticoagulation regimen adequately reduces the incidence of recurrent ischemia and limits iatrogenic bleeding. In this review, we will discuss the advances in ACS pharmacotherapy, review the recent trials evaluating these drugs, and discuss the major dilemmas in interpreting and implementing their findings.

Original languageEnglish
Article number318
JournalUnknown Journal
Issue number4
StatePublished - Apr 2013


Dive into the research topics of 'Acute coronary syndromes: advances in antithrombotics.'. Together they form a unique fingerprint.

Cite this